BRCA1

What the laboratory says this test is for

Solid Tumor Genomics from Quest Advanced Diagnostics - Precision medicine is an emerging approach for disease prevention and treatment that takes individual variability into account. This next-generation sequencing (NGS) panel along with the computational resources and tools that process and analyze the data, allows the characterization of individual patients and tumor types. Guidelines exist for using results from many of these genes for selection of FDA approved therapies. This NGS panel can accurately and sensitively sequence more target genes with less DNA, with reduced cost, time and labor as compared with more limited sequencing methods and the physician can become aware of alternative treatments available to the patient based on presence of mutations in other genes the physicians might not have considered. Microsatellite instability (MSI) and tumor mutation burden (TMB) are also included. The panel allows the generation of diverse data obtained and analyzed in real-time, enabling enrollment in specific clinical trials, and adaptation of treatment strategies.

What the laboratory says this test is for

The Hereditary Breast Cancer Panel includes 18 genes associated primarily with hereditary breast and possibly other cancers. This can include, but is not limited to, cancers of the breast, colon, endometrium, stomach, urinary tract, ovary, pancreas, prostate, and other tissues. Individuals with a positive result (pathogenic or likely pathogenic variant detected) have an increased risk for developing certain cancers relative to that of the general population.

What the laboratory says this test is for

The Guideline Based Hereditary Cancer Panel includes 32 genes associated with a broad spectrum of hereditary cancers. This can include, but is not limited to, cancers of the breast, colon, endometrium, stomach, urinary tract, ovary, pancreas, prostate, rectum, and other tissues. Individuals with a positive result (pathogenic or likely pathogenic variant detected) have an increased risk for developing certain cancers relative to that of the general population.

What the laboratory says this test is for

The Comprehensive Hereditary Cancer Panel includes 66 genes associated with a broad spectrum of hereditary cancers. This can include, but is not limited to, cancers of the breast, colon, endometrium, stomach, urinary tract, ovary, pancreas, prostate, rectum, neuroendocrine system, thyroid, adrenal glands, paraganglia, and other tissues. Individuals with a positive result (pathogenic or likely pathogenic variant detected) have an increased risk for developing certain cancers relative to that of the general population.